SCHEMBL4494946

SCHEMBL4494946

CC(C(N)=O)n1c(C(=O)N(C)C)c2c(c(O)c1=O)C(=O)N(Cc1ccc(F)c(Cl)c1)CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.33
PIK3CB P42338 2/20 0.32
GPR52 Q9Y2T5 1/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32
PSENEN Q9NZ42 1/20 0.32
HSP90AA1 P07900 2/20 0.31
TNIK Q9UKE5 1/20 0.31
HTR2A P28223 2/20 0.31
HTR2C P28335 1/20 0.31
HTR2B P41595 1/20 0.31
APP P05067 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
GRM2 Q14416 1/20 0.30
PIK3CD O00329 1/20 0.30
PIK3CA P42336 1/20 0.30
PIK3CG P48736 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2113536 0.92 AKR1B1 (0.35) AKR1B1PIK3CBHSP90AA1TNIKHTR2A
SCHEMBL4494915 0.89 AKR1B1 (0.33) AKR1B1PIK3CBHSP90AA1HTR2AHTR2C
SCHEMBL4483837 0.86 AKR1B1 (0.36) AKR1B1PIK3CBGPR52HTR2AGRM2
SCHEMBL31060990 0.86 AKR1B1 (0.36) AKR1B1PIK3CBTNIKHTR2AGRM2
SCHEMBL4479511 0.86 AKR1B1 (0.36) AKR1B1PIK3CBTNIKHTR2AGRM2
SCHEMBL4489034 0.86 AKR1B1 (0.38) AKR1B1HSP90AA1HTR2AGRM2PIK3CA
SCHEMBL4481021 0.85 AKR1B1 (0.35) AKR1B1PIK3CBHSP90AA1HTR2AHTR2C
SCHEMBL4494956 0.85 AKR1B1 (0.37) AKR1B1GPR52HTR2AGRM2PIK3CA
SCHEMBL4488414 0.85 AKR1B1 (0.35) AKR1B1PIK3CBPSEN1PSEN2APH1B
SCHEMBL4490977 0.83 AKR1B1 (0.42) AKR1B1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US claimed
EP-1725556-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005087768-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO claimed
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179196-A1 Hiv integrase inhibitors REV1, TYMP, POLR2H AKR1B1 2248/4885PIK3CB 259/4885GPR52 3479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.